Don't Panic! Novartis Is Still Invested In CAR-T Despite 2Q Silence
Executive Summary
Novartis AG's CAR-T cell therapy CTL019, set to be the first in this class to achieve a US FDA filing, might not be an immediate blockbuster owing to its tricky treatment logistics, small initial indication and a lack of physician and patient exposure, but it is still a game changer in immuno-oncology, says Dr. Oz Azam, Novartis's head of cell therapies.
You may also be interested in...
CAR-T Update: Kite's Filing Coming Soon
With all eyes on the race to get the autologous cell immunotherapies to market, Kite announces it could soon see late-stage data on its lead candidate.
Juno ROCKETs On Fast Clinical Hold Resolution
The FDA lifted a clinical hold on the Phase II ROCKET clinical trial for Juno's lead CAR-T therapy candidate JCAR015 less than a week after it was instituted, allowing the company to proceed without using fludarabine in a pre-conditioning chemotherapy regimen.
COVID-19 Serology Templates: FDA Updates Sponsor Template, Adds Home Test Document
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.
Need a specific report? 1000+ reports available
Buy Reports